Z
Zephyrm Biotech
Pluripotent stem cell-derived therapies for degenerative diseases
About Zephyrm Biotech
Zephyrm Biotechnologies Co. Ltd., founded in 2018, is a clinical-stage biotechnology company headquartered in Beijing, China, that focuses on developing stem cell drugs. The company has established a production base for creating standardized, off-the-shelf, and low-cost cell-based drugs.
Working with the Chinese Academy of Sciences and the Beijing Institute for Stem Cell and Regeneration, Zephyrm has developed technologies for a pipeline of products derived from pluripotent stem cells (PSCs). Their lead candidate, ZH901, is a cell therapy designed to treat conditions involving injury, inflammation, and degeneration by secreting cytokines to reduce inflammation and growth factors to promote healing. The company utilizes a ready-to-use strategy that enables clinicians to thaw cryopreserved products and formulate them into cellular injections. Zephyrm's entire production process for cellular reagents is serum-free to mitigate safety risks.
The company is conducting clinical trials for its PSC-derived cellular drug, CAStem cell injection, for various conditions. Phase I/II trials were approved by China's NMPA in 2020 for acute respiratory distress syndrome (ARDS) and pulmonary fibrosis caused by COVID-19, both of which have been completed. As of late 2024, Zephyrm is preparing for Phase 3 trials for its cell therapy in treating graft-versus-host disease (GvHD) and acute exacerbation of interstitial lung disease (AE-ILD), with plans to start in 2025. Further trials are planned for conditions like meniscus injuries, Parkinson's disease, and age-related macular degeneration.
Zephyrm has raised significant funding to support its research and development, including a Series A round in 2019 and a ¥200 million (US$29 million) Series B financing in 2023. The company filed for an IPO on the Hong Kong stock exchange to fund its upcoming Phase 3 trials. To support future commercialization, Zephyrm has built a factory in Beijing and plans to establish a larger manufacturing plant in Zhongshan City.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Suzhou Shi, China
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Apr 2023 | $28M | $110M | CCB Trust | ↗ |
| SPINOUT✓Other financing | Jan 2018 | $0 | — | Chinese Academy Of Sciences | — |
Growth signals
Latest recorded traffic for Zephyrm Biotech is 590 monthly website visits, up 145.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- CTCCB Trust
Other known investors1 additional known investor
Chinese Academy Of Sciences
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zephyrm Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zephyrm Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.